In this Issue:
Anastrozole vs tamoxifen for DCIS in postmenopausal women
Surveillance testing in breast cancer survivors
Cost-effectiveness of pertuzumab in HER2+ metastatic disease
Risk factors for breast cancer in childhood cancer survivors
Late risk for recurrence with ER+ disease
Neratinib in HER2+ breast cancer brain metastases
Nanoparticle- vs solvent-based paclitaxel in neoadjuvant therapy
Afatinib- vs trastuzumab-based regimens in HER2+metastatic disease
Neratinib after trastuzumab-based adjuvant therapy in HER2+ disease
Letrozole can be given concomitantly with adjuvant breast RT
Initial palliative chemotherapy is common in HER2+ disease
Please login below to download this issue (PDF)